WO2007033292A3 - Combination therapy for controlled carbohydrate digestion - Google Patents

Combination therapy for controlled carbohydrate digestion Download PDF

Info

Publication number
WO2007033292A3
WO2007033292A3 PCT/US2006/035761 US2006035761W WO2007033292A3 WO 2007033292 A3 WO2007033292 A3 WO 2007033292A3 US 2006035761 W US2006035761 W US 2006035761W WO 2007033292 A3 WO2007033292 A3 WO 2007033292A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination therapy
carbohydrate digestion
compositions
controlled carbohydrate
controlled
Prior art date
Application number
PCT/US2006/035761
Other languages
French (fr)
Other versions
WO2007033292A2 (en
Inventor
Alan Watson
Laura Brass
Bard J Geesaman
Vaughn Kailian
Original Assignee
Elixir Pharmaceuticals Inc
Alan Watson
Laura Brass
Bard J Geesaman
Vaughn Kailian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elixir Pharmaceuticals Inc, Alan Watson, Laura Brass, Bard J Geesaman, Vaughn Kailian filed Critical Elixir Pharmaceuticals Inc
Priority to CA002622558A priority Critical patent/CA2622558A1/en
Priority to EP06803558A priority patent/EP1931359A4/en
Publication of WO2007033292A2 publication Critical patent/WO2007033292A2/en
Publication of WO2007033292A3 publication Critical patent/WO2007033292A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions that include combinations of agents that inhibit carbohydrate degradation, decrease formation or severity of intestinal gas, and/or modulate insulin signalling or blood glucose levels are described. Methods of administering these compositions are also described, for example, to reduce or prevent post-prandial glucose spikes.
PCT/US2006/035761 2005-09-14 2006-09-13 Combination therapy for controlled carbohydrate digestion WO2007033292A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002622558A CA2622558A1 (en) 2005-09-14 2006-09-13 Combination therapy for controlled carbohydrate digestion
EP06803558A EP1931359A4 (en) 2005-09-14 2006-09-13 Combination therapy for controlled carbohydrate digestion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71753605P 2005-09-14 2005-09-14
US60/717,536 2005-09-14

Publications (2)

Publication Number Publication Date
WO2007033292A2 WO2007033292A2 (en) 2007-03-22
WO2007033292A3 true WO2007033292A3 (en) 2007-06-28

Family

ID=37865568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/035761 WO2007033292A2 (en) 2005-09-14 2006-09-13 Combination therapy for controlled carbohydrate digestion

Country Status (4)

Country Link
EP (1) EP1931359A4 (en)
CN (1) CN101325959A (en)
CA (1) CA2622558A1 (en)
WO (1) WO2007033292A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605302A1 (en) * 2005-04-20 2006-11-02 Kissei Pharmaceutical Co., Ltd. Combined pharmaceutical preparation for treatment of type 2 diabetes
AU2006311601A1 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904769A (en) * 1985-12-13 1990-02-27 Bayer Aktiengesellschaft Highly pure acarbose
US5004838A (en) * 1986-09-09 1991-04-02 Takeda Chemical Industries, Ltd. Inosose derivatives, production and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514549A (en) * 2004-09-14 2008-05-08 エリクシアー ファーマシューティカルズ， インコーポレイテッド Combination therapy for controlled carbohydrate digestion
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904769A (en) * 1985-12-13 1990-02-27 Bayer Aktiengesellschaft Highly pure acarbose
US5004838A (en) * 1986-09-09 1991-04-02 Takeda Chemical Industries, Ltd. Inosose derivatives, production and use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICAL THERAPEUTICS, vol. 20, no. 3, pages 497 - 504 *
DATABASE CAPLUS STN; 1998, LETTIERI ET AL.: "Effects of Beano on the tolerablility and pharmacodynamics of acarbose", XP003015695 *
DATABASE MEDLINE 2003, SCHEEN A.J.: "Current management strategies for coexisting diabetes mellitus and abesity", XP003014841 *
DRUGS, vol. 63, no. 12, pages 1165 - 1184 *
See also references of EP1931359A4 *

Also Published As

Publication number Publication date
EP1931359A2 (en) 2008-06-18
EP1931359A4 (en) 2009-04-01
CN101325959A (en) 2008-12-17
CA2622558A1 (en) 2007-03-22
WO2007033292A2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2007005590A (en) Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof.
PH12016501607A1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
WO2007041365A3 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
TW200740804A (en) Glucokinase activators
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
UA95464C2 (en) Pyridopyrazine derivatives and use thereof
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
MY137477A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
WO2008016643A3 (en) Certain chemical entities, compositions, and methods
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
WO2008011603A3 (en) Modulating notch1 signaling pathway for treating neuroendocrine tumors
WO2010042886A3 (en) Pyrones for the treatment of metabolic disorders
WO2009068659A3 (en) Novel disease treatment by predicting drug association
UA83057C2 (en) Substituted thiazole-benzoisothiazole dioxide derivatives and use of the same
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2007149875A8 (en) Compositions and methods for treating, preventing and/or reversing type-1 diabetes
WO2006135925A3 (en) Methods to reduce oxalate concentration by administration of oxalate oxidase crystals
WO2005060960A3 (en) Use of histamine to treat bone disease
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2004069194A3 (en) Use of the oxidoreductase ncb50r for diagnosings and treating diabetes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680042515.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006803558

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2622558

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2174/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/003631

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE